Cargando…

Efficacy and safety of twice-daily glycopyrrolate in patients with stable, symptomatic COPD with moderate-to-severe airflow limitation: the GEM1 study

BACKGROUND: The purpose of this study was to confirm the efficacy and safety of twice-daily glycopyrrolate 15.6 µg, a long-acting muscarinic antagonist, in patients with stable, symptomatic, chronic obstructive pulmonary disease (COPD) with moderate-to-severe airflow limitation. METHODS: The GEM1 st...

Descripción completa

Detalles Bibliográficos
Autores principales:	LaForce, Craig, Feldman, Gregory, Spangenthal, Selwyn, Eckert, Joerg H, Henley, Michelle, Patalano, Francesco, D’Andrea, Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2016
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4907493/ https://www.ncbi.nlm.nih.gov/pubmed/27354782 http://dx.doi.org/10.2147/COPD.S100445

Ejemplares similares

Once-daily indacaterol 75 μg in moderate- to-severe COPD: results of a Phase IV study assessing time until patients’ perceived onset of effect
por: Siler, Thomas M, et al.
Publicado: (2014)

Cost-effectiveness of twice-daily indacaterol/glycopyrrolate inhalation powder for the treatment of moderate to severe COPD in the US
por: Rajagopalan, Krithika, et al.
Publicado: (2018)

Efficacy and safety of glycopyrrolate in patients with COPD by reversibility: pooled analysis of GEM1 and GEM2 12-week studies
por: Ohar, Jill A, et al.
Publicado: (2019)

The 24-h FEV(1) time profile of olodaterol once daily via Respimat® and formoterol twice daily via Aerolizer® in patients with GOLD 2–4 COPD: results from two 6-week crossover studies
por: Feldman, Gregory J, et al.
Publicado: (2014)

Dose-response to inhaled glycopyrrolate delivered with a novel Co-Suspension™ Delivery Technology metered dose inhaler (MDI) in patients with moderate-to-severe COPD
por: Fabbri, Leonardo M., et al.
Publicado: (2016)

192 Efficacy and Safety of Combined Mometasone Furoate/Formoterol 100/10ìG Twice Daily in Subjects with Asthma Inadequately Controlled on Low-Dose Inhaled Corticosteroids
por: Meltzer, Eli, et al.
Publicado: (2012)

Effect of smoking status on lung function, patient-reported outcomes, and safety among COPD patients treated with glycopyrrolate inhalation powder: pooled analysis of GEM1 and GEM2 studies
por: Tashkin, Donald P., et al.
Publicado: (2019)

Efficacy of Nebulized Glycopyrrolate on Lung Hyperinflation in Patients with COPD
por: Siler, Thomas M., et al.
Publicado: (2021)

Impact of baseline clinical features on outcomes of nebulized glycopyrrolate therapy in COPD
por: Tashkin, Donald P., et al.
Publicado: (2021)

Airflow obstruction: is it asthma or is it COPD?
por: Rogliani, Paola, et al.
Publicado: (2016)

Functional respiratory imaging assessment of budesonide/glycopyrrolate/formoterol fumarate and glycopyrrolate/formoterol fumarate metered dose inhalers in patients with COPD: the value of inhaled corticosteroids
por: van den Berge, Maarten, et al.
Publicado: (2021)

Is once enough? Understanding the preferences of COPD and asthma patients for once- versus twice-daily treatment
por: Horne, Rob
Publicado: (2013)

Combination therapy for airflow limitation in COPD
por: Ghanei, Mostafa, et al.
Publicado: (2012)

Not every irreversible airflow obstruction is COPD
por: Baddini-Martinez, José
Publicado: (2016)

In Vitro Effect of Different Airflow Rates on the Aerosol Properties of Nebulized Glycopyrrolate in the eFlow® Closed System and Tiotropium Delivered in the HandiHaler®
por: Ohar, Jill A., et al.
Publicado: (2020)

24-h bronchodilation and inspiratory capacity improvements with glycopyrrolate/formoterol fumarate via co-suspension delivery technology in COPD
por: Reisner, Colin, et al.
Publicado: (2017)

The Relationship between COPD Assessment Test (CAT) Scores and Severity of Airflow Obstruction in Stable COPD Patients
por: Ghobadi, Hassan, et al.
Publicado: (2012)

Comparison of once-daily versus twice-daily dosing of valsartan in patients with chronic stable heart failure
por: Anand, Inder S, et al.
Publicado: (2010)

Effect of Gender on Lung Function and Patient-Reported Outcomes in Patients with COPD Receiving Nebulized Glycopyrrolate
por: Ohar, Jill A, et al.
Publicado: (2020)

Impact of Comorbidity Prevalence and Cardiovascular Disease Status on the Efficacy and Safety of Nebulized Glycopyrrolate in Patients with COPD
por: Putcha, Nirupama, et al.
Publicado: (2021)

Dose response of umeclidinium administered once or twice daily in patients with COPD: a randomised cross-over study
por: Church, Alison, et al.
Publicado: (2014)

Effect of Erdosteine on COPD Exacerbations in COPD Patients with Moderate Airflow Limitation
por: Calverley, Peter MA, et al.
Publicado: (2019)

Airflow limitation or static hyperinflation: which is more closely related to dyspnea with activities of daily living in patients with COPD?
por: Nishimura, Koichi, et al.
Publicado: (2011)

Practical guide to choosing dabigatran 150 mg twice daily or apixaban 5 mg twice daily for patients with atrial fibrillation
por: Kobayashi, Zen, et al.
Publicado: (2019)

Parental and life-course influences on symptomatic airflow obstruction
por: Li, Lok Sze Katrina, et al.
Publicado: (2020)

A phase IIb randomized, chronic-dosing, incomplete block, cross-over study of glycopyrronium, delivered via metered dose inhaler, compared with a placebo and an active control in patients with moderate-to-severe COPD
por: Kerwin, Edward M., et al.
Publicado: (2018)

A randomized, controlled, repeat-dose study of batefenterol/fluticasone furoate compared with placebo in the treatment of COPD
por: Crim, Courtney, et al.
Publicado: (2020)

Lung function efficacy and symptomatic benefit of olodaterol once daily delivered via Respimat(®) versus placebo and formoterol twice daily in patients with GOLD 2–4 COPD: results from two replicate 48-week studies
por: Koch, Andrea, et al.
Publicado: (2014)

Effect of SGRQ-Defined Chronic Bronchitis at Baseline on Treatment Outcomes in Patients with COPD Receiving Nebulized Glycopyrrolate
por: Tashkin, Donald P, et al.
Publicado: (2021)

Effect of Gender on Lung Function and Patient-Reported Outcomes in Patients with COPD Receiving Nebulized Glycopyrrolate [Corrigendum]
Publicado: (2021)

Absence of airflow obstruction on spirometry: can it still be COPD?
por: Neder, José Alberto, et al.
Publicado: (2020)

Efficacy of Glycopyrrolate in Primary Hyperhidrosis Patients
por: Lee, Hyun Ho, et al.
Publicado: (2012)

Glycopyrrolate in toxic exposure to ammonia gas
por: Bhalla, A, et al.
Publicado: (2011)

Glycopyrrolate-Induced Black Hairy Tongue
por: Prabha, Neel, et al.
Publicado: (2020)

Addressing unmet needs in the treatment of COPD
por: Patalano, Francesco, et al.
Publicado: (2014)

Once-daily fluticasone furoate/vilanterol 100/25 mcg versus twice daily combination therapies in COPD – mixed treatment comparisons of clinical efficacy
por: Stynes, Gillian, et al.
Publicado: (2015)

Once– versus twice–daily tacrolimus: are the formulations equivalent?
por: Ciszek, Michał
Publicado: (2013)

Neutrophil extracellular trap (NET) formation characterises stable and exacerbated COPD and correlates with airflow limitation
por: Grabcanovic-Musija, Fikreta, et al.
Publicado: (2015)

COPD assessment test and severity of airflow limitation in patients with asthma, COPD, and asthma–COPD overlap syndrome
por: Kurashima, Kazuyoshi, et al.
Publicado: (2016)

Diagnosis of COPD and clinical course in patients with unrecognized airflow limitation
por: Murphy, Daniel E, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_4609cr0is93511651rrogsguar